

KEY COMPANY DATA

Current Stock Price	\$0.004
Target Price	\$0.04
% Upside	1000%
Market Cap	\$1.6 million
Business	Healthcare Technology
Shares Outstanding	344 million
Float	
Stock Exchange	OTC
SEC Reporting	Yes (1-A)

COMPANY OPERATIONS

Ehave is a leading healthcare services and technology company, focused on progressing psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health. Together with our network of scientists and mental health professionals, we are on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues, leveraging clinical data to help us achieve optimal patient outcomes. Ehave's operations span across the entire USA, Canada, Jamaica, and Australia. Additional information on Ehave can be found on the Company's website at: www.ehave.com

INVESTOR HIGHLIGHTS

- **Healthcare Data Analytics.** Continuous and reliable data is the missing key needed to create personalized care. Show your care through our mobile-first solution, backed by science and created for mental health analysis and monitoring, mood and emotions tracking through vocal biomarkers www.metahealthu.com
- **Mobile Ketamine treatment service.** KetaDASH offers ketamine for treatment resistant depression, anxiety, PTSD, and other conditions. After a short telemedicine visit, an experienced nurse will arrive at your location of choice to administer the sublingual treatment. www.ketadash.com
- **Psychedelic Treatments.** Through their holdings in **Mycotopia Therapies** (OTC:TPIA), the company primary focus is on mushroom and psychedelic treatment opportunities. www.mycotopiatherapies.com
- **Genetic Testing.** Help identify how an individual's DNA profile can affect their response to hallucinogenic drugs. The information contained in this report is based on research related to specific genetic polymorphisms and their influence on pharmacodynamics, pharmacokinetics and mental health risk factors for psychedelics use.

STOCK PERFORMANCE

1 Month	00.00%
3 Months	00.00%
6 Months	00.00%
12 Months	00.00%

COMPANY INFO

CEO: Benjamin Kaplan

Ehave, Inc.
100 SE 2nd St. Suite 2000
Miami, FL 33131

Telephone: (954) 233-3511

Email: ir@ehave.com

Website: www.ehave.com

Twitter: @Ehaveinc1

LinkedIn: [linkedin.com/company/ehave/](https://www.linkedin.com/company/ehave/)

RESEARCH SUMMARY

Ehave is a healthcare technology company, which is focused on healthcare data collection, management, and analytics for the mental health and wellness market.

Their core mission is to create safe and effective therapeutics that will help achieve better patient outcomes when dealing with brain health issues such as depression, anxiety, and PTSD.


As economies across the globe emerge from pandemic restrictions many nations are facing a growing mental health crisis resulting from economic stress and long waiting lines for psychiatric care.

Increases in mental health disorders, such as anxiety, depression, and post-traumatic stress disorder (PTSD) are resulting in renewed demand for alternative mental health treatments, which could result in higher consumer demand for Ehave services into 2023.

This business model could position Ehave operations as sort of a hedge to any economic recession.

For these reasons, Ludlow Research has initiated coverage on Ehave, Inc. (OTC:EHVVF) with a 'speculative' valuation target of **\$0.04 per share**, or \$14 million market valuation.





HEALTHCARE DATA MANAGEMENT

MetaHealthU is a mobile application platform that empowers individuals to take complete control of their health and their healthcare data. With MetaHealthU, users can securely track all their health data from wearables, Electronic Health Records Systems (EHRs), Doctors and Medical Labs.

www.metahealthu.com

More importantly, MetaHealthU gives ownership of health data back to the patient allowing them to share their data securely to research firms, or other medical professionals.

MetahealthU seeks to develop a comprehensive dataset marketplace for clinical trials and drug development firms.

The Healthcare Data market is projected to be valued at \$81.3 billion by 2030

Data Management in Healthcare

Healthcare data management is the process of storing, protecting, and analyzing data pulled from diverse sources. Managing the wealth of available healthcare data allows health systems to create holistic views of patients, personalize treatments, improve communication, and enhance health outcomes.

Web3 in Healthcare Infrastructure

Integrating Web3 in healthcare can give the power over data back to users and help handle a structured data management system. The data stored in Web3 is distributed, personalized and traceable, eventually bringing transparency, accessibility and affordability to the healthcare ecosystem.



MOBILE IV THERAPY TREATMENTS

KetaDASH is a mobile psychedelic therapy clinic that offers psychedelic therapy and IV's in the comfort of customers home or office. www.ketadash.com

Psychedelic Treatments

Ketamine is a promising new treatment option for a variety of mental health conditions, particularly treatment-resistant cases, due to how it affects the brain and how quickly it starts working. From individual treatment sessions to group meditation, the company's KetaDASH service offers various ketamine treatments in the San Francisco and Miami Area.

A typical KetaDASH experience incorporates a prescribing doctor, a nurse for administration and monitoring, and psychotherapists for integration, all from the comfort of the patient's home. You can visit KetaDASH on Instagram at www.instagram.com/ketadash.usa

IV Drip Detox and Hangover Treatments

The company offers a blend of IV fluids, electrolytes, vitamins, and medications to restore vitamins in your body and help you overcome your hangover symptoms quickly.

Customers can choose among a variety of different IV infusions with fluids, essential vitamins, minerals, and electrolytes to enhance your health and wellness. The company IV hydration therapy drips are specially formulated to help you meet your unique wellness goals.



GENETIC TESTING FOR PSYCHEDELIC TREATMENT

HaluGen Psychedelics Genetic Test is a pharmacogenomic test to help identify how an individual's DNA profile can affect their response to hallucinogenic drugs. The information contained in this report is based on research related to specific genetic polymorphisms and their influence on pharmacodynamics, pharmacokinetics and mental health risk factors for psychedelics use.

Ehave announced a partnership with **Entheon Biomedical Corp.** (CSE: ENBI) (OTCQB: ENTBF) HaluGen Life Sciences Inc. to use its psychedelics genetic test kit. KetaDASH will become one of the first psychedelic companies to use precision medicine to test patients by using HaluGen's expanded psychedelics genetic testing panel, which analyzes a series of relevant DNA biomarkers and utilizes pre-screening mental health surveys in order to provide insights into an individual's risk and potential of adverse reactions with the use of ketamine.

HTR2A GENE - SEROTONIN SENSITIVITY

Approximately 20% of people carry an HTR2A genetic variant which can increase serotonin receptor density, potentially making them more susceptible to stronger hallucinogenic effects. These individuals should be more cautious when considering classical psychedelic therapies

CYP2B6 GENE - KETAMINE METABOLISM

The way your body metabolizes ketamine, a fast-acting anesthetic with hallucinogenic properties, is influenced by the CYP2B6 gene. This gene encodes a liver enzyme that helps metabolize ketamine in your bloodstream. 10–20% of people carry the CYP2B6*6 genetic variant which causes them to metabolize ketamine up to 2x to 3x slower than normal.

CYP2D6 GENE - LSD, MDMA & AYAHUASCA METABOLISM

The way your body metabolizes LSD, MDMA and ayahuasca, is influenced by the CYP2D6 gene. This gene encodes a liver enzyme that helps metabolize these drugs in your bloodstream. 5–10% of people carry the CYP2D6 genetic variant which causes them to metabolize LSD, MDMA and ayahuasca up to 2x slower than normal.

PSYCHDELEIC TREATMENTS



PENDING MYCOTOPIA THERAPIES MERGER

Mycotopia Therapies (OTC: [TPIA](#)) signed a definitive agreement to complete a triangular merger with **Ei.Ventures**, an early-stage tech company empowering mental wellness through psychoactive compounds, nutraceuticals and technology, to form **PSLY.COM**.

The transaction between Mycotopia Therapies and Ei.Ventures will be structured as a triangular merger. The two companies will form a new holding company, PSLY.COM, and operate as subsidiaries after the merger. PSLY.COM will apply for a NASDAQ listing.

Mycotopia Therapies primary focus is on mushroom and psychedelic opportunities. The company has been performing most of its research in Jamaica, where psilocybin is legal, as well as working with one of the largest cannabis labs in the Netherlands to develop psychedelics to jointly license certain molecules to be used in psychedelic medicine.

Ei.Ventures' ambition is to deliver governmental approved therapeutic treatment options that address the current global mental healthcare pandemic. By leveraging blockchain, emerging technologies and the Metaverse, Ei.Ventures intends to create a safe, efficient, and secure way to provide telehealth services in general, as well as for psychoactive therapeutics.

Disclosures and Disclaimer:

THE MATERIAL HEREIN DOES NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY JURISDICTION WHERE OR TO ANY PERSON TO WHOM IT WOULD BE UNAUTHORIZED OR UNLAWFUL TO DO SO.

The material herein is provided for informational purposes only and should not be construed as investment advice or an offer or solicitation to buy or sell securities.

This reports contains certain statements that may be deemed “forward-looking” statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by law, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Ludlow Research (“Ludlow”), and its parent company Ludlow Consulting, LLC, are not registered broker-dealers or investment advisers with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”), or any state securities regulatory authority.

Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Ludlow does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. Ludlow, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encouraged to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Ludlow was compensated three thousand six hundred dollars for research report, and holds business relationships through affiliate company, and thus should be considered a conflict of interest when reviewing this information. Investments is speculative ‘penny stocks’, as defined by the SEC, may involve a high degree of risk.

INVESTORS ARE HIGHLY ENCOURAGED TO CONSULT WITH A FINANCIAL ADVISOR BEFORE MAKING ANY AND ALL INVESTMENT DECISIONS.

AI Venturetech, Inc.

Thomas Bustamante

Strategic Advisor

LinkedIn: www.linkedin.com/in/tombustamante/

Ludlow Research

Twitter: <https://twitter.com/ludlowresearch>

Website: www.ludlowresearch.com

Email: info@ludlowresearch.com
